Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

NCT07660198 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Disease

Interventions

BIOLOGICAL: PG4
BIOLOGICAL: 20-valent pneumococcal conjugate vaccine (20vPnC)

Sponsor

Pfizer